Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways
- PMID: 11090077
Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways
Abstract
Somatic mutations of the receptor tyrosine kinase Flt3 consisting of internal tandem duplications (ITD) occur in 20% of patients with acute myeloid leukemia. They are associated with a poor prognosis of the disease. In this study, we characterized the oncogenic potential and signaling properties of Flt3 mutations. We constructed chimeric molecules that consisted of the murine Flt3 backbone and a 510-base pair human Flt3 fragment, which contained either 4 different ITD mutants or the wild-type coding sequence. Flt3 isoforms containing ITD mutations (Flt3-ITD) induced factor-independent growth and resistance to radiation-induced apoptosis in 32D cells. Cells containing Flt3-ITD, but not those containing wild-type Flt3 (Flt3-WT), formed colonies in methylcellulose. Injection of 32D/Flt3-ITD induced rapid development of a leukemia-type disease in syngeneic mice. Flt3-ITD mutations exhibited constitutive autophosphorylation of the immature form of the Flt3 receptor. Analysis of the involved signal transduction pathways revealed that Flt3-ITD only slightly activated the MAP kinases Erk1 and 2 and the protein kinase B (Akt) in the absence of ligand and retained ligand-induced activation of these enzymes. However, Flt3-ITD led to strong factor-independent activation of STAT5. The relative importance of the STAT5 and Ras pathways for ITD-induced colony formation was assessed by transfection of dominant negative (dn) forms of these proteins: transfection of dnSTAT5 inhibited colony formation by 50%. Despite its weak constitutive activation by Flt3-ITD, dnRas also strongly inhibited Flt3-ITD-mediated colony formation. Taken together, Flt3-ITD mutations induce factor-independent growth and leukemogenesis of 32D cells that are mediated by the Ras and STAT5 pathways. (Blood. 2000;96:3907-3914)
Similar articles
-
AML-associated Flt3 kinase domain mutations show signal transduction differences compared with Flt3 ITD mutations.Blood. 2005 Jul 1;106(1):265-73. doi: 10.1182/blood-2004-07-2942. Epub 2005 Mar 15. Blood. 2005. PMID: 15769897
-
RGS2 is an important target gene of Flt3-ITD mutations in AML and functions in myeloid differentiation and leukemic transformation.Blood. 2005 Mar 1;105(5):2107-14. doi: 10.1182/blood-2004-03-0940. Epub 2004 Nov 9. Blood. 2005. PMID: 15536149
-
[Mutations of growth factor receptor Flt3 in acute myeloid leukemia: transformation of myeloid cells by Ras-dependent and Ras-independent mechanisms].Dtsch Med Wochenschr. 2002 Oct 18;127(42):2195-200. doi: 10.1055/s-2002-34942. Dtsch Med Wochenschr. 2002. PMID: 12397548 German.
-
Role of FLT3 in leukemia.Curr Opin Hematol. 2002 Jul;9(4):274-81. doi: 10.1097/00062752-200207000-00003. Curr Opin Hematol. 2002. PMID: 12042700 Review.
-
Flt3 receptor tyrosine kinase as a drug target in leukemia.Curr Pharm Des. 2004;10(16):1867-83. doi: 10.2174/1381612043384394. Curr Pharm Des. 2004. PMID: 15180525 Review.
Cited by
-
Targeting cell cycle regulators in hematologic malignancies.Front Cell Dev Biol. 2015 Apr 9;3:16. doi: 10.3389/fcell.2015.00016. eCollection 2015. Front Cell Dev Biol. 2015. PMID: 25914884 Free PMC article. Review.
-
Targeting FLT3-ITD signaling mediates ceramide-dependent mitophagy and attenuates drug resistance in AML.Blood. 2016 Oct 13;128(15):1944-1958. doi: 10.1182/blood-2016-04-708750. Epub 2016 Aug 18. Blood. 2016. PMID: 27540013 Free PMC article.
-
The STAT5 Inhibitor Pimozide Displays Efficacy in Models of Acute Myelogenous Leukemia Driven by FLT3 Mutations.Genes Cancer. 2012 Jul;3(7-8):503-11. doi: 10.1177/1947601912466555. Genes Cancer. 2012. PMID: 23264850 Free PMC article.
-
BPR1J-097, a novel FLT3 kinase inhibitor, exerts potent inhibitory activity against AML.Br J Cancer. 2012 Jan 31;106(3):475-81. doi: 10.1038/bjc.2011.564. Epub 2011 Dec 20. Br J Cancer. 2012. PMID: 22187040 Free PMC article.
-
Clinical implications of combination therapy with quizartinib and craniospinal irradiation for refractory acute myeloid leukemia positive for FMS-like tyrosine kinase 3-internal tandem duplication with central nervous system involvement.Clin Case Rep. 2022 Feb 4;10(2):e05384. doi: 10.1002/ccr3.5384. eCollection 2022 Feb. Clin Case Rep. 2022. PMID: 35140970 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Miscellaneous